Competing interests
WO2020109570A1 - cancer, HT
ONCOLOGY, PATHOLOGY
CD reports personal fees from Novartis, Roche, MSD Oncology, Daiichi Sankyo, Molecular Health, Astra Zeneca, Merck; grants from Myriad Genetic and Roche; Stock and Other Ownership Interests from Sividon Diagnostics (until 2016); and has patent applications WO2015114146A1 and WO2010076322A1- therapy response, and WO2020109570A1 - cancer immunotherapy pending, and a patent Software (VMscope digital pathology). HT reports other from Pierre Fabre, other from Pfizer Pharma, other from Mundipharma, other from ClinSol, other from Novartis, other from Lilly, other from AMGEN, other from Grünenthal, other from Vifor, other from AstraZeneca, other from Mylan, other from BMS, during the conduct of the study. JUB reports personal fees from Amgen, Astra Zeneca, Exact Science, MSD Oncology, Lilly, Novartis, Pfizer, Sysmex, Roche, and Sonoscape. KR reports personal fees from AstraZeneca, personal fees from Pfizer, personal fees from MSD, outside the submitted work. PW reports honoraria from AstraZeneca, MSD Oncology, Eisai, Novartis/ Pfizer, Roche Pharma AG, Amgen, Pfizer; Consulting or Advisory Role from Amgen, Astra Zeneca, MSD Oncology, Novartis, Roche Pharma AG, Tesaro, PharmaMar; Travel, Accommodations, Expenses from RochePharma AG, outside the submitted work. SK reports personal fees from Lilly, Roche, Genomic Health, Novartis, Amgen, Celgene, Daiichi Sankyo, Astra Zeneca, Somatex, MSD, Pfizer, Puma Technology, PFM medical, non-financial support from Roche, Daiichi Sankyo, Lilly, Sonoscape outside the submitted work, and a relationship with the WSG study group as co-director. SL reports grants and other from Abbvie, grants and other from Amgen, grants and other from AstraZeneca, grants and other from Celgene, grants, personal fees and other from Daiichi-Sankyo, grants and other from Novartis, grants and other from Pfizer, grants and other from Roche, other from BMS, other from Eirgenix, other from Lilly, other from Merck, other from MSD, other from SeaGen, other from Prime/Medscape, other from Puma, other from Samsung, other from Pierre Fabre, grants from Teva, grants from Vifor, grants from Immunomedics, personal fees from Chugai, outside the submitted work; In addition, Dr. Loibl has a patent EP14153692.0 pending. TL reports scientific talks from MSD, Pfizer, Novartis, Teva, Tesaro, Roche, Amgen, Clovis, Lilly, GSK, Gilead; Travel/Kongress-Support from Pharmamar, Roche, Pfizer, MSD, Celgene, Clovis, Daiichi Sankyo; Consulting or Advisory Role from Amgen, Roche, Tesaro, MSD, Pfizer, Lilly, Myriad, Esai, GSK, Gilead, Daiichi Sankyo outside the submitted work. No other potential conflict of interest relevant to this article was reported.